Abstract
Background Highly pathogenic H5 avian influenza A has caused sporadic human infections, increasing the risk for potential human-to-human spread. In 2024, the U.S. experienced outbreaks among poultry and cattle, prompting enhanced surveillance.
Objective To evaluate an H5 testing algorithm in subjects with respiratory symptoms presenting for routine care during low influenza A virus circulation.
Design Observational study using clinical- and research-developed nucleic acid amplification tests (NAATs) and pooled screening methods.
Setting Academic medical center in Boston, MA.
Participants 5,400 symptomatic individuals contributing 6,935 respiratory specimens from June 23 to August 28, 2024.
Measurements Specimens underwent initial respiratory pathogen testing per clinical protocols, which did not routinely include influenza due to low summer-month prevalence. Influenza A-positive specimens were subtyped using a clinical assay for H5 assessment. SARS-CoV-2-negative specimens not tested for influenza were screened in pooled batches. Positive pools were deconvoluted to individual specimens and screened for H5 using quantitative polymerase chain reaction.
Results Influenza A was detected in 40 of 6,935 specimens (0.6%), comprising 35 of 5,400 unique subjects (0.7%). No H5 infections were identified. Of the 35 influenza-positive individuals, 10 cases (29%) were found through research-specific screening of SARS-CoV-2–negative specimens. No deaths attributed to influenza were recorded.
Limitations Single center design, convenience sampling, absence of ocular specimens, and minimal sampling in high-risk areas may limit generalizability.
Conclusion Expanded influenza testing using pooled NAATs successfully identified low-prevalence influenza A and ruled out H5 in this cohort. These data support targeted influenza screening to enhance surveillance for emerging subtypes rather than a broad-based clinical testing strategy for influenza A testing.
Primary Funding Source Supported by institutional resources and Center for Disease Control and Prevention contracts.
Competing Interest Statement
J.A.B. has received funding to his institution for other research projects from Pfizer Inc., Analog Devices Inc., and the Steven & Alexandra Cohen Foundation. He has been a consultant for Diasorin, Roche Diagnostics and Flightpath Biosciences. P.C.S. is a co-founder and shareholder of Delve Bio. She was a co-founder and shareholder of Sherlock Biosciences (sold to Orasure in December 2024) and was a non-executive board member and shareholder of Danaher Corporation (stepping down in December 2024). S.E.T. has received research funding from SeLux Diagnostics and has served as a consultant for CarbX. All others report no disclosures.
Funding Statement
This study was funded by Massachusetts Department of Public Health and Center for Disease Control and Prevention through the US Public Health Pathogens Genomics Centers of Excellence award (MADPH Contract Number INTF5104H78W22195363). Additional support was provided from CDC through two Broad Agency Announcement contract subawards from the Broad Institute of MIT and Harvard (Federal Contract Numbers 75D30123C17983 and 75D30122C15113) and the Office of Advanced Molecular Detection, through Cooperative Agreement Number CK22-2204.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Mass General Brigham gave ethical approval for this work (Mass General Brigham Human Research Protection Program).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
